Otsuka Pharmaceutical secured U.S. regulatory approval for its anti‑APRIL antibody to treat IgA nephropathy (IgAN). The company announced accelerated approval after regulators cleared the therapy for patients with progressive kidney damage from the autoimmune condition. Otsuka named the antibody sibeprenlimab (Voyxact in some reports) and positioned the approval as the first in an emerging class targeting APRIL biology. The decision gives nephrologists a new targeted option for a disease that can progress to renal failure and dialysis. Otsuka’s chief medical officer framed the approval as expanding treatment choices for clinicians managing IgAN. The approval will trigger regulatory and commercial planning as payors and nephrology centers assess how the new agent fits into existing care pathways.